What if conventional-dose imatinib fails?

Blood

Volumn 109, Issue 12, 2007, Pages 5068-5069

  Schiffer, Charles A ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILITONIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; HUMAN; NOTE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 34250002566     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-081794     Document Type: Note

References (2)

1. Druker BJ, Guilhot F, O'Brien SG, et al, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.NEngl J Med. 2006; 355:2408-17.
2. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.